1
Kevin Rodzinak
Armstrong Donna J, Hu Essa H, Kelly Michael J Iii, Layton Mark E, Li Yiwei, Liang Jun, Rodzinak Kevin J, Rossi Michael A, Sanderson Philip E, Wang Jiabing: Inhibitors of akt activity. Merck & Co, Armstrong Donna J, Hu Essa H, Kelly Michael J Iii, Layton Mark E, Li Yiwei, Liang Jun, Rodzinak Kevin J, Rossi Michael A, Sanderson Philip E, Wang Jiabing, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, December 21, 2006: WO/2006/135627 (19 worldwide citation)

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


2
Kevin Rodzinak
Furuyama Hidetomo, Goto Yasuhiro, Kawanishi Nobuhiko, Layton Mark E, Mita Takashi, Naya Akira, Ogino Yoshio, Onozaki Yu, Rodzinak Kevin J, Sakamoto Toshihiro, Sanderson Philip E, Wang Jiabing: Inhibitors of akt activity. Merck & Co, Banyu Pharmaceutical, Furuyama Hidetomo, Goto Yasuhiro, Kawanishi Nobuhiko, Layton Mark E, Mita Takashi, Naya Akira, Ogino Yoshio, Onozaki Yu, Rodzinak Kevin J, Sakamoto Toshihiro, Sanderson Philip E, Wang Jiabing, Leff Matthew A, December 10, 2009: WO/2009/148916 (10 worldwide citation)

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms, preferably Akt1. The invention also provides for compositions comprising such inhibitory compounds and methods ...


3
Kevin Rodzinak
Layton Mark E, Rodzinak Kevin J, Kelly Michael J Iii, Sanderson Philip E: N-alkyl-azacycloalkyl nmda/nr2b antagonists. Merck & Co, Layton Mark E, Rodzinak Kevin J, Kelly Michael J Iii, Sanderson Philip E, MERCK 126 East Lincoln Avenue Rahway New Jersey 07065 0907, October 26, 2006: WO/2006/113471 (3 worldwide citation)

Compounds represented by Formula (I): and/or pharmaceutically acceptable salts, individual enantiomers and stereoisomers thereof, are effective as NMDA/NR2B antagonists useful for treating conditions such as pain, Parkinson’s disease, Alzheimer’s disease, epilepsy, depression, anxiety, ischemic brai ...


4
Kevin Rodzinak
Layton Mark E, Rodzinak Kevin J, Sanderson Philip E: Inhibitors of akt activity. Merck & Co, Layton Mark E, Rodzinak Kevin J, Sanderson Philip E, MERCK 126 East Lincoln Avenue Rahway New Jersey 07065 0907, June 12, 2008: WO/2008/070134 (3 worldwide citation)

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


5
Kevin Rodzinak
Layton Mark E, Rodzinak Kevin J, Kelly Michael J Iii, Sanderson Philip E: 1,3-disubstituted heteroaryl nmda/nr2b antagonists. Merck & Co, Layton Mark E, Rodzinak Kevin J, Kelly Michael J Iii, Sanderson Philip E, MERCK 126 East Lincoln Avenue Rahway New Jersey 07065 0907, February 16, 2006: WO/2006/017409 (2 worldwide citation)

Compounds represented by Formula I: (wherein A, B, D, P, Q, R1, R2, R3, W and Y are described herein) or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson’s disease, Alzheimer’s disease, ...


6

7

8
Kevin Rodzinak
Armstrong Donna J, Hu Essa H, Kelly Michael J Iii, Layton Mark E, Li Yiwei, Liang Jun, Rodzinak Kevin J, Rossi Michael A, Sanderson Philip E, Wang Jiabing: Inhibitors of akt activity. Merck &Amp Amp Co, February 21, 2008: KR1020077028878

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


9

10
Kevin Rodzinak
Layton Mark E, Rodzinak Kevin J, Kelly Michael J Iii, Sanderson Philip E: N-alkyl-azacycloalkyl nmda/nr2b antagonists. Merck &Amp Co, tanmeng sheng duanjia rong, April 16, 2008: CN200680012726

Compounds represented by Formula (I): and/or pharmaceutically acceptable salts, individual enantiomers and stereoisomers thereof, are effective as NMDA/NR2B antagonists useful for treating conditions such as pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brai ...



Click the thumbnails below to visualize the patent trend.